CTIS2022-502432-39-00进行中（未招募）1 期
ION356-CS1: A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered ION356 in Patients with Pelizaeus-Merzbacher Disease - ION356-CS1
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 73
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 17（—）
- 性别
- Male
入选标准
- •1. Previous diagnosis of PMD with genetic confirmation of PLP1 gene duplication with molecular confirmation by a CLIA, CE-marked, or equivalent lab provided by the Investigator at Screening., 2. Clinical phenotype and brain imaging consistent with a diagnosis of PMD, 3. Male between the ages of 2 and 17 years, inclusive, at the time of informed consent, 4. Able and willing to meet all study requirements (in the opinion of the Investigator), including travel to Study Center, procedures, measurements, and visits
排除标准
- •01. > 2 copies of the PLP1 gene, 10. Known brain or spinal disease or previous spinal surgery that would interfere with the LP process, CSF circulation, or safety assessment, including tumors or abnormalities by MRI or computed tomography, subarachnoid hemorrhage, spinal stenosis or curvature, Chiari malformation, syringomyelia, tethered spinal cord syndrome, and connective tissue disorders such as Ehlers-Danlos syndrome and Marfan syndrome, 11. History of severe post-LP headache and/or blood patch, 12. Hospitalization for any major medical or surgical procedure involving general anesthesia within 12 weeks prior to Screening or planned during the study, 13. Have any other conditions, which, in the opinion of the Investigator, would make the participant unsuitable for inclusion, or could interfere with participation in or completion of the study, 02. Clinically significant abnormalities in medical history (e.g., previous acute coronary syndrome or evidence of renal impairment within 6 months of Screening, major surgery within 3 months of Screening) or physical examination, 03. Unwillingness to comply with study procedures, including follow-up, as specified by this protocol, or unwillingness to cooperate fully with the Investigator, 04. Any contraindication or unwillingness to undergo MRI (e.g., metal implants, claustrophobia, agitation, or motor symptoms of a severity that precludes MRI scans), 05. Treatment with another investigational drug, biological agent, or device within 1 month of Screening, or 5 half-lives of the investigational agent, whichever is longer, 06. Previous treatment with an oligonucleotide (including small interfering ribonucleic acid) within 4 months of Screening if a single dose was received, or within 12 months of Screening if multiple doses were received; or history of hypersensitivity to ION356 or its excipients; or history of hypersensitivity to any ASO. This exclusion does not apply to vaccines (both mRNA and viral vector vaccines), 07. History of gene therapy or cell transplantation, or any experimental brain surgery, 08. Current obstructive hydrocephalus, 09. Presence of a functional ventriculoperitoneal shunt for the drainage of CSF or an implanted CNS catheter
研究者
相似试验
招募中
1 期
A Phase 1/2a study of PF-07220060 in Participants with Advanced Solid TumorsCTIS2024-512120-11-00Pfizer Inc.337
招募中
1 期
A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination with Axitinib in Subjects with Advanced Renal Cell CarcinomaAdvanced Renal Cell CarcinomaMedDRA version: 20.0Level: SOCClassification code: 10029104Term: Neoplasms benign malignant and unspecified (incl cysts and polyps) Class: 2MedDRA version: 21.1Level: PTClassification code: 10067946Term: Renal cell carcinoma Class: 100000004864CTIS2023-509604-15-00AstraZeneca AB179
已完成
2 期
A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination with Pembrolizumab in HLA-A2+ Participants with NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer (study 208471)lung cancerNL-OMON52531GlaxoSmithKline9
进行中（未招募）
1 期
A study of NY-ESO-1 T-cells (GSK3377794) alone and in combination with Pembrolizumab in NSCLC patients.EUCTR2018-003949-42-NLGlaxoSmithKline Research & Development Ltd54
已完成
1 期
A clinical trial to evaluate the safety and immunogenicity of HBI Pentavalent (DTwP-Hb-Hib[Liquid]) combination vaccine in two age groups of healthy subjects.CTRI/2015/04/005688Human Biologicals Institute55